AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02711618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UltraShape Contour I V3
Description: Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
Study NCT02602054 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: Standard left thoracotomy
Study NCT02602054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: - Indomethacin:~Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:~Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:~Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:~First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg~- Acetaminophen~Administer 1 full cycle, in the first fourteen days of life in preterm infants:~Acetaminophen 15 mg/kg every 6 hours for 3 days
Study NCT03242551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days.
Study NCT02779725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SCC
Description: Automated self-management coaching paired to symptom reports during daily symptom monitoring call
Study NCT02779725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse Practitioner
Description: Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
Study NCT02779725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DSS
Description: A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
Study NCT02779725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AT
Description: An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
Study NCT02779725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Severity
Description: Automated patient-reporting of 11 common cancer treatment symptoms
Study NCT00779051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem 10mg tablets
Study NCT00779051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem 10mg tablets
Study NCT02274636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: A comparison between discs and gel
Study NCT02045966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail
Description: Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
Study NCT02045966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCV 3DAA FDC
Description: DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
Study NCT02045966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Study NCT01009203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
Study NCT01009203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
Study NCT02558192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG
Description: 1 vials q12 for 15 days
Study NCT02558192 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: 1 vials q12 for 15 days
Study NCT02796001 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: human rhinovirus
Description: human rhinovirus
Study NCT02796001 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no intervention
Description: 4 volunteers were not re-challenged and did not participate in the second challenge
Study NCT03623685 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurement of uterocervical angle
Description: We will measure between internal cervikal os and external cervical os. After we will draw a line between anterior uterine wall and internal cervical os. Then we will measure angle between two lines
Study NCT02974088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neem-based lotion plus louse comb
Description: Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
Study NCT02974088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neem-based lotion plus grooming comb
Description: Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
Study NCT02886767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin to skin contact
Description: The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
Study NCT02039791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimotuzumab
Description: 200mg/w,weekly, 6 weeks
Study NCT02039791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6, d1，1 cycle/21d, 2 cycles
Study NCT02039791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m2, d1~1 cycle/21d, 2 cycles.
Study NCT03423823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept 25 MG/ML [Zaltrap]
Description: Anti-VEGF injection
Study NCT03423823 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Anti-VEGF standard of care injection
Study NCT02853721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPTH
Description: iPTH assay six hours after surgery
Study NCT02853721 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no dosage of iPTH
Description: Ca and P on postoperative day 1 and 2
Study NCT04773613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental SLP
Description: SLP was given to the infant during bottle-feeding.
Study NCT04773613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental SEP
Description: SEP was given to the infant during bottle-feeding.
Study NCT00550368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological intervention: Enteropathogenic E. coli
Description: 5x10\^8 or 1x10\^9 organisms of EPEC were administered to all participants.
Study NCT04193267 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim Rapid2 Transcranial Magnetic Simulation
Description: A non-invasive method of brain stimulation
Study NCT03462472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg heating
Description: Immersion of lower legs in a circulating water bath at a temperature of 42 degrees Celsius
Study NCT03462472 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower leg transcutaneous electrical nerve stimulation (TENS)
Description: Bilateral lower leg transcutaneous electrical nerve stimulation (TENS) using burst mode at a 3Hz burst rate, 100Hz frequency, and 250 µs pulse duration, sufficient to evoke skeletal muscle contraction
Study NCT02465463 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: 250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
Study NCT02465463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: flexible sigmoidoscopy
Study NCT02716467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intercessory prayer
Description: Intercessory prayer will be offered by a group of six Christian people.
Study NCT02716467 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: All participants will receive treatment by radiotherapy
Study NCT02716467 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: All participants will receive treatment by radiotherapy
Study NCT02807792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perianal access device
Description: Perianal access device
Study NCT02005081 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Actifuse SHAPE
Description: Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
Study NCT02005081 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Autograft with Demineralized Bone Matrix
Description: autograft mixed with demineralized bone matrix in cervical spine fusion.
Study NCT04331353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 1 (tailored approach)
Description: Tailored to a child's sensitization status. Components include, education, cockroach baiting, mattress and bed covers, high efficiency particulate air (HEPA) vacuum cleaner, air purifier.
Study NCT04331353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator 2 (insecticidal bait)
Description: Cockroach bait
Study NCT03622853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid (shincort)
Description: intraarticular shincort 40mg / 4ml mixed with 2% xylocaine and Normal saline
Study NCT01222637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CetuGEX™
Study NCT01381354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive exercise
Description: Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
Study NCT01381354 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV
Description: Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
Study NCT01381354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified paleolithic diet
Description: Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: 4 grams daily by mouth.
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Full Spectrum vitamin
Description: Two capsules daily.
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential - hydroxytyrosol
Description: Two capsules twice daily.
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maltodextrin fiber supplement
Description: One scoop daily.
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral boost (magnesium)
Description: Two capsules daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: 500 mg daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methyl B12
Description: Methyl B12 1000 mcg daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Taurine
Description: one gram daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: creatine
Description: one teaspoon daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: thiamine
Description: 100 mg daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: riboflavin
Description: 200 mg daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N acetylcysteine
Description: 1 gram daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: alpha lipoic acid
Description: 300 mg twice daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L acetyl carnitine
Description: 500 mg twice daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: methyl folate
Description: 1000 mcg one pill four times a week
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: coenzyme Q
Description: 100 mg daily
Study NCT01381354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meditation
Description: meditation 15 minutes daily
Study NCT01381354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self massage
Description: self massage of hands, feet, ears 15 minutes daily
Study NCT01381354 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: learning
Description: completing puzzles or learning 15 minutes daily
Study NCT01381354 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
Study NCT05291000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Role of Training and Reminder Wristwatche in Hypertension (RoT-ReWiH)
Description: The present study revealed that multiple interventions such as home visits to elderly hypertensive patients, training program, telephone counseling, and the use of medication reminder wristwatch are effective in increasing treatment adherence and self-efficacy, and in controlling blood pressure. In this direction, health professionals working in primary care are recommended that they make regular home visits, encourage patients to take responsibility for health, and organize regular and interdisciplinary training and counseling programs in the management of hypertension.
Study NCT03635307 — intervention group
Intervention type: OTHER
Intervention: End Tidal Carbon Dioxide measure
Description: End Tidal Carbon Dioxide measures before and after a volume expansion of 250ml of crystalloid in the operating room.
Study NCT03995901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FCR001
Description: FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
Study NCT01704820 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroflexion in the right colon
Study NCT01271803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Study NCT01271803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
Study NCT01176773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyaluronic acid gel
Description: Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
Study NCT00705835 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rsPSMA protein plus Alhydrogel® vaccine
Description: The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
Study NCT05397860 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation using gradual radiofrequency energy delivery with Octopus electrodes
Description: Radiofrequency ablation (RFA) will be performed by using multi-VIVA generator and Octopus electrodes. Three electrodes will be placed on the tumor under ultrasonography (US)-computed tomography (CT)/magnetic resonance (MR) fusion tool guidance. The electrodes will be cooled with saline, and radiofrequency (RF) will be applied to two of three electrodes at the same time for about 6 to 30 minutes depending on the tumor size. The temperature will be maintained at 90-100 °C. The RF energy will starts at 60 watts and increase by 10 watts every 30 seconds for the first 3 minutes, and then increases gradually by 10 watts per minute after reaching 100 watts.
Study NCT04023825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprazygomatic maxillary nerve block
Description: in the experimental group, each child will profit from the realization of a suprazygomatic maxillary nerve block.
Study NCT00196872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicine
Description: Epirbubicne is given
Study NCT00196872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given
Study NCT00196872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxol
Description: Taxol is given
Study NCT00196872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeloda
Description: Xeloda is given
Study NCT00196872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronat
Description: Ibandronat is given
Study NCT03865147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tri-Solfen Gel (Lidocaine HCl, Bupivacaine HCl, Adrenaline Acid Tartrate /Cetrimide)
Description: Investigational Drug
Study NCT03865147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA cream
Description: Active Comparator
Study NCT03865147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMLA cream
Description: Active Comparator
Study NCT03865147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post Operative Analgesia (Paracetamol, Ibuprofen)
Description: Standard of Care
Study NCT03865147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post Operative Analgesia (Paracetamol, Ibuprofen)
Description: Standard of Care
Study NCT00279773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Study NCT01384422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634
Study NCT01384422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GLPG0634
Study NCT01862640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole, OPC-34712
Description: Once-daily, tablets
Study NCT01862640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Once-daily, tablets
Study NCT02655302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sample collecting
Description: Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
Study NCT02655302 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lung function measure
Description: Measure lung function and follow it during 4 years
Study NCT04189237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: needles were inserted to Taixi (KI3), Taichong (LR3), Zusanli(ST36), Yanglingquan (GB34), contralateral to the operated leg and deqi sensation elicited at acupoints.
Study NCT03770559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal Invasive RAMPS
Description: Eligible patients diagnosed as left-side pancreatic cancer in MI-RAMPS group will be treated by minimal invasive RAMPS surgery